Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor.
Shiori SaitoJiro KikuchiDaisuke KoyamaShin SatoNaoki OsadaYoshiaki KurodaKoshi AkahaneTakeshi InukaiTakashi UmeharaYusuke FurukawaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
These findings provide a molecular basis and rationale for the inclusion of a brain-permeable LSD1 inhibitor, S2157, in treatment strategies for T-ALL with CNS involvement.